1.中国中医科学院广安门医院心血管科,北京 100053
2.中国中医科学院广安门医院预防保健科, 北京 100053
石洁,女,45岁,博士,主任医师。研究方向:心血管疾病的中西医结合诊治。
王丽昀,E-mail:liyun2108@126.com
扫 描 看 全 文
石洁,商秀洋,王丽昀.清肝降压胶囊联合卡维地洛片治疗肝经郁热型高血压合并慢性心率增快疗效观察[J].北京中医药,2022,41(10):1115-1118.
SHI Jie,SHANG Xiu-yang,WANG Li-yun.Clinical observation on Qinggan Jiangya Capsules combined with Carvedilol Capsules for hypertensive patients with chronic increased heart rate of stagnated heat of liver meridian syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(10):1115-1118.
石洁,商秀洋,王丽昀.清肝降压胶囊联合卡维地洛片治疗肝经郁热型高血压合并慢性心率增快疗效观察[J].北京中医药,2022,41(10):1115-1118. DOI: 10.16025/j.1674-1307.2022.10.008.
SHI Jie,SHANG Xiu-yang,WANG Li-yun.Clinical observation on Qinggan Jiangya Capsules combined with Carvedilol Capsules for hypertensive patients with chronic increased heart rate of stagnated heat of liver meridian syndrome[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(10):1115-1118. DOI: 10.16025/j.1674-1307.2022.10.008.
目的,2,观察清肝降压胶囊联合卡维地洛片治疗肝经郁热型高血压合并慢性心率增快患者的疗效及安全性。,方法,2,选择2018年10月―2020年7月于中国中医科学院广安门医院心血管科门诊就诊的静息心率>80次/min、肝经郁热型1、2级高血压患者122例,按照随机数字表法分为单药组和联合组。单药组予卡维地洛10 mg/次,2次/d;联合组在此基础上予清肝降压胶囊1.5 g/次,3次/d。2周后血压不达标的患者卡维地洛加量为20 mg/次,2次/d,疗程为4周。对比2组治疗前后血压、心率、中医证候评分及疗效、安全性。,结果,2,治疗2、4周2组SBP、DBP、静息心率均较治疗前降低(,P,<,0.05);治疗4周联合组SBP低于单药组(,P,<,0.05)。治疗4周后,联合组血压达标率高于单药组(,P,<,0.05);2组心率达标率、卡维地洛加量患者比例比较,差异均无统计学意义(,P,>,0.05)。治疗后2组中医证候积分均较治疗前降低(,P,<,0.05),且联合组中医证候积分低于单药组(,P,<,0.05)。联合组总有效率高于单药组(,P,<,0.05),2组治疗后均未出现不良反应。,结论,2,清肝降压胶囊联合卡维地洛可以提高合并慢性心率增快的肝经郁热型1、2级高血压患者的血压达标率,且改善患者的临床症状,疗效优于单纯卡维地洛治疗。
Objective,2,To explore the clinical effect and safety of Qinggan Jiangya Capsules combined with Carvedilol Tablets for hypertensive patients with chronic increased heart rate of stagnated heat of liver meridian syndrome.,Methods,2,122 patients with grade 1 and 2 hypertension with resting heart rate >80 beats /min of stagnated heat of liver meridian syndrome admitted to the Cardiovascular Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences from October 2018 to July 2020 were selected and randomly divided into single-drug group and combined-therapy group according to the random number table method. Single-drug group was prescribed Carvedilol 10mg Bid and combined-therapy group was prescribed Carvedilol 10 mg Bid and Qinggan Jiangya Capsules 0.9 g three times a day. Those whose blood pressure didn't reach target control were prescribed Carvedilol 20 mg Bid after two weeks and the whole course was four weeks. The blood pressure, heart rate, TCM syndrome score, curative effect and safety were compared between the two groups before and after treatment.,Results,2,After two and four weeks, not only SBP and DBP, but also rest heart rate in two groups were decreased significantly(,P,<,0.05). After 4 weeks of treatment, SBP in the combined group was lower than that in the single drug group (,P,<,0.05), the blood pressure compliance rate of combined group was higher than that of single drug group (,P,<,0.05). There was no significant difference between the two groups in heart rate compliance rate and the ratio of Carvedilol to 20 mg twice a day (,P,>,0.05).TCM syndrome scores of both groups were significantly decreased after treatment (,P,<,0.05).The TCM syndrome scores of combined-therapy group patients were significantly lower than those of single-drug group patients(,P,<,0.05).The total effective rate of TCM syndrome in combined-therapy group was significantly higher than that in single-drug group and the difference was of statistical significant(,P,<,0.05).There were no adverse reactions in both groups after treatment.,Conclusion,2,Qinggan Jiangya Capsules combined with Carvedilol can improve the blood pressure standard rate of patients with grade 1 and grade 2 hypertension accompanied with chronic heart rate increase, and improve the clinical symptoms of patients. The curative effect is better than that of Carvedilol alone.
高血压慢性心率增快清肝降压胶囊卡维地洛肝经郁热证
Hypertensionchronic increased heart rateQinggan Jiangya CapsulesCarvedilolstagnated heat of liver meridian syndrome
高血压心率管理多学科共识组. 中国高血压患者心率管理多学科专家共识(2021年版)[J]. 中国全科医学,2021,24(20):2501-2507,2519.
孙宁玲, 霍勇, 黄峻. 中国高血压患者心率现状调查[J]. 中华高血压杂志,2015,23(10):934-939.
中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56.
王夏云, 陈民, 全守霞,等. 清肝降压胶囊联合厄贝沙坦对原发性高血压患者血清脂联素,VEGF及Hcy水平的影响[J]. 现代生物医学进展,2017,17(11):2068-2071.
赵连友, 孙宁玲, 孙英贤,等. α/β受体阻滞剂在高血压治疗中应用的中国专家共识[J]. 中华高血压杂志,2016,24(6):521-526.
国家中医药管理局.中华人民共和国中医药行业标准.中医病证诊断疗效标准:ZY/T001.1-94[S].南京:南京大学出版社,1994.
施仲伟,冯颖青,林金秀,等.高血压患者心率管理中国专家共识[J/CD]. 中国医学前沿杂志(电子版),2017,9(8):29-36.
郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:292-295.
查玉玲, 李军. 高血压靶器官损害的中医临床研究进展[J]. 北京中医药,2021,40(4):436-439.
杜柏, 宋庆桥, 褚瑜光,等. 老年高血压左室肥厚患者阴阳亏虚证型与左心重构相关性研究[J]. 北京中医药,2021,40(2):128-131.
周玉,胡元会,柴若宁,等.基于CiteSpace对交感神经与高血压关系研究的可视化分析[J].中国医药导报,2021,18(26):17-23.
郭继鸿. 努力提高对慢性心率增快的重视力度[J]. 中华心脏与心律电子杂志,2013,1(1):2-3.
陈雨菲, 孔炜. 交感神经系统在血管性疾病发生发展中的研究进展[J]. 中国动脉硬化杂志,2021,29(2):106-115.
牛丹丹, 吕本艳. 原发性高血压病患者交感神经和迷走神经张力对静息心率的影响[J]. 新乡医学院学报,2020,37(5):430-432.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构